Session Details

PRL08 Pearls: Dermatopathology

Sat, Jul 18, 2:00 PM - 2:45 PM
Trianon Ballroom
0.75 CME Available Pearls
View Map

DESCRIPTION

This is a fast-paced session where each speaker will present 3 to 4 carefully selected cases that highlight essential microscopic features, key histochemical stains, and relevant immunohistochemical or molecular findings. These illustrative examples are designed to provide practical dermatopathology insights and diagnostic tools that can be readily applied in clinical practice. The session focuses on helping participants recognize inflammatory and neoplastic conditions that are often misdiagnosed, ultimately aiming to enhance diagnostic accuracy, improve workflow efficiency, and contribute to better patient outcomes.

LEARNING OBJECTIVES

1.

Identify key microscopic features and apply diagnostic skills to improve diagnosis.

2.

Identify potential ways in which stains, immunohistochemistry or molecular studies can assist in diagnosis.

SCHEDULE

2:00 PM

From Blood to Biopsy: Novel Diagnostic Approaches Using Serology and Immunohistochemical Staining

Shruti Agrawal, MD, FAAD

2:10 PM

TBD

Christine Ahn, MD, FAAD

2:20 PM

“The ones that got away: cases I missed so you won’t”

Catherine Chung, MD, FAAD

2:30 PM

Sebaceous Neoplasms and Muir-Torre Syndrome: When Can Mismatch Repair (MMR) Immunohistochemistry Affect Management?

Arlene M. Ruiz de Luzuriaga, MD, FAAD

2:40 PM

Q&A

DIRECTOR

Arlene M. Ruiz de Luzuriaga, MD, FAAD

Arlene M. Ruiz de Luzuriaga, MD, FAAD

SPEAKERS

Shruti Agrawal, MD, FAAD

Shruti Agrawal, MD, FAAD

Christine Ahn, MD, FAAD

Christine Ahn, MD, FAAD

Catherine Chung, MD, FAAD

Catherine Chung, MD, FAAD

DISCLOSURES

Shruti Agrawal, MD, FAAD

No financial relationships exist with ineligible companies.

Christine Ahn, MD, FAAD

No financial relationships exist with ineligible companies.

Catherine Chung, MD, FAAD

No financial relationships exist with ineligible companies.

Arlene M. Ruiz de Luzuriaga, MD, FAAD

No financial relationships exist with ineligible companies.